Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruserontinib vs Salvage Chemotherapy in R/R FLT3-mutated AML
NCT04716114Phase 3Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ruserontinib in acute myeloid leukemia (AML), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Mar 2021; status: recruiting.
02
Drugs
ruserontinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04716114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04716114.